Delivery Order SPE2DB24D9238-SPE2DB26FDQEB
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain division on October 17, 2025, for VABYSMO 6 mg/0.05 ml syringes valued at $5,966.88 with a firm fixed-price structure. The delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V)...
- The Defense Logistics Agency issued a delivery order valued at $1,579.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. This delivery order, awarded on October 21, 2025, with an ultimate completion date of October 23, 2025, utilizes a firm fixed-price structure with no set-aside designation. DMS Pharmaceutical Group was selected as a...
- The Defense Logistics Agency awarded a $8,950.32 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of VABYSMO 6 mg/0.05 ml syringes. The contract was awarded on July 29, 2025, with an ultimate completion date of August 19, 2025, and carries no set-aside designation. DMS Pharmaceutical Group will perform the delivery order from its Park Ridge facility. This delivery order is issued...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $11,094.20 on October 30, 2025, by the Defense Logistics Agency's Medical Supply Chain division. This firm fixed-price delivery order, without set-aside designation, represents one of numerous purchase orders issued to the vendor in October 2025 for pharmaceutical products and medical consumables to support Department of Defense healthcare...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $1,458.40 by the Defense Logistics Agency on October 21, 2025, for VABYSMO 6 mg/0.05 mL vials. This delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $46,683.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of VABYSMO 6 MG/0.05 ML VIAL 0.05ML, a pharmaceutical product, with an ultimate completion date of August 9, 2024. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $6,922.15 on September 19, 2025, by the Defense Logistics Agency's Medical Supply Chain division. The contract, designated as a firm fixed-price delivery order with no set-aside designation, calls for the delivery of Vabysmo 6mg/0.05ml, a pharmaceutical product for federal healthcare systems. Performance is scheduled to be completed by...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $6,224.44 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler located in Park Ridge, Illinois. The contract is for the supply of VABYSMO 6 MG/0.05 ML VIAL 0.05ML, with a period of performance through April 2, 2024. This delivery order is issued against DMS Pharmaceutical Group's larger indefinite delivery vehicle (IDV) contract SPE2DB, valued up to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,520.40 by the Defense Logistics Agency on October 29, 2025. This firm fixed-price delivery order, designated as a Pharmaceutical Prime Vendor Fleet contract, represents a specific purchase issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $5,966.88 by the Defense Logistics Agency on August 26, 2025. The delivery order covers VABYSMO 6 mg/0.05 mL syringes, a prescription pharmaceutical product, with an ultimate completion date of September 17, 2025. This award was not issued under a set-aside designation, allowing the vendor to compete directly in the open...
- SPE2DB24D9238Indefinite Delivery Contract
- SPE2DB24D9238-SPE2DB26FDQEBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,966.88 to DMS Pharmaceutical Group Inc. for VABYSMO 6 mg/0.05 mL syringes on October 29, 2025. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The product will be delivered to Park Ridge, Illinois, with an ultimate completion date of November 20, 2025. The contract employs firm fixed-price pricing with no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, and serves as a critical supplier within the Department of Defense's pharmaceutical supply chain. The company's underlying PPV-G GEN V IDC, awarded on November 13, 2025, carries a ceiling value of $499.9 billion and extends through December 31, 2036, positioning DMS Pharmaceutical as one of multiple regional prime vendor contractors supporting military healthcare facilities worldwide. The company's product portfolio encompasses a comprehensive range of pharmaceuticals including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceutical products, enabling it to fulfill diverse and specialized medical supply requirements across the Department of Defense healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 10/29/25 |